Oncolytics reports faster enrollment in REO 033 colorectal cancer studySep 30Regulatory decisionOncolytics BiotechSagimet Biosciences Inc.Updated
GSK registers three new Phase 3 trials spanning asthma, prostate cancer, ovarian cancerSep 30Weekly roundup, 8 itemsgepotidacinGlaxoSmithKlineUpdated
AstraZeneca registers Phase 3 ovarian cancer ADC trial and Phase 1 hMPV antibody studySep 17Weekly roundup, 3 itemsAstraZenecaAZD0543
Incyte registers Phase 3 MAESTRA 3 trial in cyclin E1-overexpressing ovarian cancerSep 1Trial updateINCB123667Incyte Corporation
Merck registers Phase 3 trial testing R-DXd maintenance in advanced ovarian cancerAug 20Trial updateDaiichi SankyoMerck & Co., Inc.
Outlook Therapeutics details LYTENAVA US launch prep in Q3 FY2026 updateAug 14Quarterly updatebevacizumab-vikgOutlook Therapeutics, Inc.
Inhibrx reports Q2 2026 results, sets Q3 PFS readout for INBRX-106Aug 13Quarterly updateInhibrx Biosciences, Inc
Adagene reports mid-2026 results, muzastotug data across CRC and HCC trialsAug 12Clinical readoutAdagene Inc
Cypherpunk's Leap Therapeutics subsidiary aligns with FDA on Phase 3 trial for sirexatamabAug 12Quarterly updateCypherpunk Technologies Inc.
Cardiff Oncology reports Q2 2026 results, plans Phase 3 mCRC trial for early 2027Aug 11Quarterly updateCardiff Oncology
CytomX reports Q2 2026 results, advances Varseta-M toward first registrational studyAug 6Quarterly updateCytomX Therapeutics
Coherus reports Q2 2026 results, flags October data update for tagmokitugAug 5Quarterly updateCoherus Oncology, Inc.toripalimab-tpzi
Outlook Therapeutics posts Phase 3 results for ONS-5010 in wet AMD trialAug 3Trial updatebevacizumabOutlook Therapeutics, Inc.
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarterJul 29Quarterly updateCorcept Therapeuticsmifepristone
Outlook Therapeutics wins FDA approval for Lytenava in wet AMDJul 24Regulatory decisionbevacizumab-vikgOutlook Therapeutics, Inc.
Outlook Therapeutics grants options and bonuses tied to ONS-5010 BLA progressJul 23PeoplebevacizumabOutlook Therapeutics, Inc.
Outlook Therapeutics posts NORSE THREE results for ONS-5010 in retinal disordersJul 17Trial updatebevacizumabOutlook Therapeutics, Inc.
GSK posts bepirovirsen QT results; registers Mo-Rez ovarian, endometrial Phase 3 trialsJul 10Weekly roundup, 6 itemsbepirovirsencamlipixant
BeiGene's LBL-007/tislelizumab colorectal cancer trial posts resultsJun 30Trial updatealcestobartBeiGene
Outlook Therapeutics posts NORSE EIGHT phase 3 results for ONS-5010 in wet AMDJun 30Trial updatebevacizumabOutlook Therapeutics, Inc.
Sign inSign in